A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice

Calcified Tissue International

Volumn 91, Issue 3, 2012, Pages 196-203

  Ponnapakkam, Tulasi ^a   Katikaneni, Ranjitha ^a   Suda, Hirofumi ^b   Miyata, Shigeru ^c   Matsushita, Osamu ^d   Sakon, Joshua ^e   Gensure, Robert C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c CHUBU UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF ARKANSAS   (United States)

Author keywords

Animal models; Bone density technology; DXA; Osteoporosis therapy

Indexed keywords

ANABOLIC AGENT; CALCIUM; PARATHYROID HORMONE[1-33] COLLAGEN BINDING DOMAIN PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE TISSUE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG TISSUE LEVEL; FEMALE; HAIR FOLLICLE; HISTOLOGY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SKIN CULTURE; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT DURATION;

ANABOLIC AGENTS; ANIMALS; BACTERIAL PROTEINS; BONE DENSITY; COLLAGEN; COLLAGENASES; FEMALE; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; PARATHYROID HORMONE; RECOMBINANT FUSION PROTEINS;

EID: 84866017861     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9626-1     Document Type: Article

References (25)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis- related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475
2. National Osteoporosis Foundation (2011) About osteoporosis. Bone Health Basics. http://www.nof.org/aboutosteoporosis/bonebasics/whybonehealth. Accessed 12 July 2012
3. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254
4. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483-489
5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
6. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916
7. Anonymous (2002) Forteo (teriparatide) package insert. Eli Lilly, Indianapolis
8. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown- Augsburger PL, Sato M, Hock JM (2003) Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33:372-379
9. Barbehenn EK, Lurie P, Wolfe SM (2001) Osteosarcoma risk in rats using PTH 1-34. Trends Endocrinol Metab 12:383
10. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041-1045
11. Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D (2007) Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res 22:1534-1547
12. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286
13. Ponnapakkam T, Katikaneni R, Miller E, Ponnapakkam A, Hirofumi S, Miyata S, Suva LJ, Sakon J, Matsushita O, Gensure RC (2011) Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. Calcif Tissue Int 88:511-520
14. Katikaneni R, Ponnapakkam A, Miller E, Ponnapakkam T, Gensure RC (2009) A new technique for precisely and accurately measuring lumbar spine bone mineral density in mice using clinical dual energy X-ray absorptiometry (DXA). Toxicol Mech Methods 19:225-231
15. Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, Kobayashi S, Sonobe H, Okabe A (2003) Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect Immun 71:5371-5375
16. Shimamoto S, Tamai E, Matsushita O, Minami J, Okabe A, Miyata S (2005) Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergentresistant membranes of Madin-Darby canine kidney cells. Microbiol Immunol 49:245-253
17. Ponnapakkam T, Katikaneni R, Nichols T, Tobin G, Sakon J, Matsushita O, Gensure RC (2011) Prevention of chemotherapyinduced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone. J Endocrinol Invest 34:e392-e397
18. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ (1996) Genetic variability in adult bone density among inbred strains of mice. Bone 18:397-403
19. Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS (1997) Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 99:391-395
20. Ellegaard M, Jorgensen NR, Schwarz P (2010) Parathyroid hormone and bone healing. Calcif Tissue Int 87:1-13
21. Katikaneni R, Ponnapakkam T, Bradford E, Pasala S, Matsushita O, Sakon J, Gensure RC (2010) A novel parathyroid hormone fusion protein causes sustained increases in bone mineral density in ovarectomized rats after monthly or single dosing. Paper presented at 32nd American Society of Bone and Mineral Research (ASBMR) annual meeting, 13-18 October, Toronto, Canada
22. Tawfeek H, Bedi B, Li JY, Adams J, Kobayashi T, Weitzmann MN, Kronenberg HM, Pacifici R (2010) Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 5:e12290
23. Katikaneni R, Ponnapakkam T, Suda H, Miyata S, Sakon J, Matsushita O, Gensure RC (2011) Treatment for chemotherapyinduced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer 2012 131:E813-E821
24. Foley J, Dann P, Hong J, Cosgrove J, Dreyer B, Rimm D, Dunbar M, Philbrick W, Wysolmerski J (2001) Parathyroid hormonerelated protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development 128:513-525
25. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W (2001) Beta-catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105:533-545